Articles tagged with Cancer Medication
The University of Pennsylvania School of Medicine is conducting a smoking cessation study that will provide participants with medication and individual counseling. Volunteers must be at least 18 years old, in good health, and motivated to quit smoking, and are expected to participate for nearly one full year.
Dr. Korsmeyer's work on BCL-2 identified its role in blocking cell death and established a mammalian apoptotic pathway. His research has significantly impacted cancer treatment and our understanding of biology and medicine.
Researchers are developing functional nanoparticles that can be linked to biological molecules, enabling rapid analysis of biopsy tissue from cancer patients. These nanoprobes using quantum dots can monitor the effectiveness of drug therapy and deliver controlled amounts of drugs into genetically classified tumor cells.
Researchers suggest that a person's sleep/wake cycle, also called the circadian rhythm, may be linked to their cancer prognosis. Disrupted circadian rhythms can lead to reduced melatonin production, which can spur cancer-causing mutations in cells.
The American Association for Cancer Research has honored scientists who have made significant contributions to the prevention, detection, and treatment of cancer. These awards recognize outstanding achievements in basic research, clinical care, therapeutics, and prevention.
A team of researchers has developed a novel lung cancer treatment using nanoparticle cluster bombs, which have shown promise in treating cancerous lung cells. The new delivery system could potentially be used to target cancer cells while leaving healthy cells alone.
The new guidelines recommend limiting treatment to patients at expected risk for metastatic disease and only evaluating drugs with demonstrated clinical activity. The guidelines also require significant proportion of patients to show decline or no increase in PSA and prostate-cancer specific survival.
A study published in The Journal of Nuclear Medicine found that PET scans are more effective than CT scans in early assessment of patients' responses to imatinib mesylate therapy. The researchers concluded that 18F-FDG PET is an excellent prognostic tool for predicting treatment response in gastrointestinal stromal tumors.
A study of over 88,000 women found no significant difference in pancreatic cancer risk between aspirin users and non-users. However, extended regular aspirin use was associated with a 58% increased risk, while higher doses were linked to an 86% increased risk.
A national survey found that most American adults support routine cancer screening, but many have misconceptions about its benefits. The study suggests a need to balance messages and reduce overtesting and overtreatment.
Researchers are investigating the role of broccoli-derived chemicals in preventing prostate cancer. The study aims to better understand how these substances inhibit prostate cancer growth and identify potential biomarkers for future intervention trials.
The American Association for the Advancement of Science names WMAP satellite and Sloan Digital Sky Survey as key discoveries confirming a dark, expanding universe dominated by 73% dark energy. Scientists also identified genes increasing mental illness risk and reported global warming impacts.
Researchers found that oral drug ZD1839 suppressed the growth of ER-negative breast cancer cells and delayed the formation of tumors in transgenic mice. The treatment also reduced proliferation of normal breast cells by 20.3% and tumor cells by 42%. However, long-term safety data are needed for further research.
The Penn State project aims to create interactive maps of cancer rates in specific geographic areas, enabling better planning and evaluation of cancer interventions. Based on prostate and colorectal cancers, the model can be expanded to other states, utilizing available screenings and interventions to reduce cancer burden.
The study aims to identify new forms of therapy and hope for those at high risk of developing cancer. Six institutions will design and conduct experiments to test the cancer prevention potential of substances affecting various processes involved in cancer's formation and spread.
The American Society of Hematology has awarded Gary Gilliland and Janet Rowley for their significant contributions to hematology research. Dr. Gilliland's work on the molecular pathogenesis of leukemia and discovery of a cause for hypereosinophilic syndrome have provided new ways to understand cancer, while Dr. Rowley's discoveries of ...
A phase II trial found that AMD-3100, a new drug, increases the availability of stem cells in cancer patients undergoing transplantation. This boosts the chances of successful transplantation and may reduce the number of collections needed.
A new study found that three months is too soon to judge a patient's response to Gleevec, a common CML treatment. Researchers discovered that achieving a complete cytogenetic response had a significant impact on long-term outcome and survival rates.
Breast cancer tumors that become resistant to tamoxifen over-produce a protein called MTA-1, which can be used to predict treatment outcomes and guide therapy selection. Testing for MTA-1 prior to treatment may help devise more aggressive strategies to combat breast cancer.
Researchers found that paroxetine reduces levels of endoxifen, an active metabolite of tamoxifen, in breast cancer patients. This decrease was more pronounced in women with a normal CYP2D6 genotype, suggesting potential implications for tamoxifen treatment outcomes.
Researchers discovered a new metabolite, endoxifen, which is present in higher concentrations than previously thought and varies with genetic composition. This finding suggests that tamoxifen's effectiveness may be influenced by individual differences in metabolism.
A new study found that chemotherapy and radiation together is more effective than sequential treatment in preserving the voice box, with 88% of patients still having their voice after two years. Overall survival rates were similar for all three treatment options.
Researchers analyzed DNA samples from 127 patients with gastrointestinal stromal tumors (GISTs) to determine if a KIT tyrosine kinase mutation was present and its impact on Gleevec response. Patients with favorable lab results had an 84 percent chance of partial remission, while those with unfavorable results did not respond.
New class of drugs targets specific molecules within brain cancer cells, slowing growth and reducing side effects. Three drugs - ZD6474, SB431542, and AEE788 - demonstrate significant promise in treating glioblastoma and other types of brain tumors.
BAY 43-9006 shows promise as a treatment for kidney cancer, with 42% of patients experiencing tumor shrinkage. The compound targets both Raf kinase and VEGFR2, inhibiting tumor growth and angiogenesis.
Researchers found tumor shrinkage and arrest in patients with advanced malignancies treated with SU11248, an oral histone deacetylase inhibitor SAHA, and BAY 43-9006, targeting angiogenesis and cell growth signaling molecules. These preliminary results confirm the promise of these therapeutic approaches.
A phase II trial found that 42% of patients with metastatic kidney cancer experienced at least a 25% reduction in tumor size, with 6 patients experiencing a 50% or greater response. The study's innovative design validated a new approach to phase II trial design.
Researchers at Baylor College of Medicine have identified a novel secretory protein specific to neuroblastoma, which could provide clues to differentiating between aggressive tumors and those that are more likely to respond to treatment. Additionally, scientists have discovered selective inhibitors of key protein kinases implicated in ...
A study by St. Jude Children's Research Hospital found that the anti-cancer drug CCI-779 can prevent abnormal brain growth and reverse seizures in lab mice lacking the Pten gene. The researchers used a mouse model to demonstrate that mTor plays multiple roles in the brain, driving cell growth and signaling pathways.
Researchers will discuss novel targets for controlling cancer growth, such as the circadian rhythm of cells and VEGF, a key player in tumor angiogenesis. The conference also aims to improve radiotherapy effectiveness for head and neck cancers by tailoring therapy to individual tumors.
Researchers at Fox Chase Cancer Center discovered a novel DNA-repair gene mutation that causes resistance to cancer drugs, particularly in colorectal cancer. The defective MED1 enzyme interferes with chemotherapy's effectiveness, making cancers resistant to widely used treatments.
The UCI Cancer Center is one of six institutions nationwide chosen to conduct early-phase clinical trials testing cancer prevention agents. The center will receive over $2.2 million initially, with a focus on assessing the potential of various substances in preventing cancer recurrence.
Researchers demonstrate that removing beta-1 integrin gene prevents breast cancer growth in mice, halting tumor progression and even regressing advanced cancers. However, some tumors spontaneously recur over time, highlighting the need for further investigation into mechanisms of resistance.
Current drinkers who consume at least 30 grams of alcohol daily have an 80% higher risk of breast cancer compared to nondrinkers. Alcohol is associated with a strong increase in hormonally responsive types of breast cancer, including lobular and ER+/PR+ tumors.
The FDNY Tobacco Cessation Program, a free, multi-modal approach, shows a 10-fold increase in quit rates compared to previous studies. At 6 months, 39% of participants were tobacco-free, with the program's success attributed to its combination nicotine replacement therapy and behavior-stress support.
Dr. Yuan Chang discovered human herpesvirus 8 (KSHV) in 1994 and has since studied its biology to understand how it causes cancer. Her work has transformed understanding of the most common malignancy in people infected with HIV.
Gefinitib, a designer drug targeting the epidermal growth factor receptor, has shown efficacy in treating advanced non-small cell lung cancer. In a phase II clinical trial, 43% of patients experienced symptom improvement and 12% showed partial radiographic responses.
Researchers at Johns Hopkins Kimmel Cancer Center have discovered a gene silencer that blocks cancer cells' ability to repair themselves after chemotherapy and radiation. By reducing the production of targeted repair proteins, the silencer enables cancer cells to become susceptible to therapy.
A new model of cancer development suggests that Id1 activation may be crucial for tumor growth, contradicting previous research. The study, which used mice exposed to carcinogens, found that tumors developed faster in mice without the Id1 gene.
A new combination treatment using arsenic trioxide and radiation has shown promising results in treating glioblastoma, a previously incurable form of brain cancer. The study found that exposing glioblastoma cells to radiation within two hours of receiving a dose of arsenic trioxide amplified the effects of radiation treatment on its own.
Researchers found a significant reduction in breast cancer risk among women taking statins and non-statin lipid-lowering drugs. The study analyzed data from over 7,500 older white women and found a 60-70% lower risk of developing breast cancer.
A new study found that adding aprepitant to standard treatment for nausea and vomiting can effectively prevent these symptoms following chemotherapy. The medication reduced nausea and vomiting both on the day of chemotherapy administration and in the days that followed.
A laboratory study found that methylnaltrexone blocked increases in HIV entry and replication when immune cells are exposed to therapeutic doses of morphine. The study suggests that the drug may improve care for patients with AIDS who require pain relief, potentially reducing the risk of severe constipation.
A clinical trial found that taking letrozole after five years of tamoxifen therapy can substantially increase the chance of remaining cancer-free. The study showed a significant reduction in breast cancer recurrence and deaths among women on letrozole compared to those on the placebo.
A clinical trial has found that letrozole significantly improves the long-term outlook for breast cancer survivors, reducing the risk of recurrence by 43%. The study showed that women taking letrozole had a lower risk of disease recurrence and deaths from breast cancer compared to those on the placebo.
A new study shows that letrozole picks up where tamoxifen leaves off in preventing breast cancer recurrence. Women who have been treated for breast cancer and are now cancer-free may need to consider additional treatment options, such as letrozole, based on their individual risk factors.
Researchers developed a molecular test that detects residual cancer cells with high accuracy, outperforming standard cytogenetic analysis. The test predicts disease progression and can be used to stratify patients according to their level of remission, potentially shortening clinical trial duration.
Researchers at Penn aim to understand factors influencing poor prostate cancer outcomes among African-American men, including biological, environmental, and behavioral aspects. The study's findings may help develop better tools for prevention and treatment, ultimately improving clinical outcomes for this underserved population.
A study found racial and ethnic disparities in pain perception, diagnosis, and treatment across various specialties. Disparities were seen in emergency departments, cancer clinics, chronic pain, and disability, with African Americans and Hispanics facing unequal access to pain medication and treatment.
A recent study of early-stage breast cancer patients found that tamoxifen is effective in reducing recurrence and mortality regardless of body mass index. However, obesity was linked to increased risks of second cancers and all-cause mortality.
A new treatment approach uses a Trojan Horse technique to deliver a radioactive isotope into breast cancer cells, slowing tumour growth. The therapy combines EGF with Indium-111, exploiting the natural uptake of EGF by breast cancer cells.
Researchers identified a link between LKB1, an enzyme that reduces blood glucose levels, and AMPK, which inhibits cell growth. This connection could lead to more effective anti-diabetes drugs, such as metformin, also being used to treat cancer. The study found that LKB1 plays a crucial role in preventing tumor growth by activating AMPK.
The European CanCer Organisation warns that the definition of a trial sponsor may lead to the collapse of independent clinical trials, particularly in children's cancers and rare adult cancers. Publicly funded clinical trials will be forced to stop due to financial and administrative burdens.
A new study by ATAC found that Anastrozole enhances disease-free survival and reduces breast cancer recurrence, but increases bone fracture risk. The fracture rate peaks at 18-24 months before stabilizing, suggesting the overall benefit of Anastrozole remains
Researchers have discovered a novel molecular mechanism that explains why certain Hsp90 inhibitors are effective against tumor cells while being non-toxic to normal tissues. This breakthrough has significant implications for the development of targeted cancer therapies and may lead to new treatments for various types of cancer.
Researchers identify key genes involved in cancer development, including BRAF, and develop targeted drugs to combat the disease. A new approach to cancer treatment is being explored by targeting mutated genes, offering new hope for more efficient treatments.
Long-term health consequences of cancer therapy affect nearly all organ systems in pediatric cancer survivors, leading to impaired physical functioning and mental health issues. Women are 40% more likely than men to experience long-term problems.
Patients who traveled farther for cancer treatment had improved overall and progression-free survival rates, suggesting that access to information and resources plays a crucial role in cancer outcomes. The study's findings highlight the importance of considering travel distance as a potential factor in phase II clinical trial results.
Researchers have developed a program to train cancer registrars to track patients' comorbidities, increasing the accuracy of cancer profiles and treatment outcomes. The method is easy for registrars to learn and has shown significant improvements in patient care.
TM has shown promising results in treating Wilson's disease by reducing copper levels, while also inhibiting tumor growth and inflammation in various cancers. The drug's potential to treat inflammatory fibrosis diseases is being explored through ongoing clinical trials.